Dial takeover
This article was originally published in The Rose Sheet
Executive Summary
Shareholders of record as of the close of business Feb. 24 will vote on Henkel's proposed acquisition of Dial during March 24 special meeting at firm's Scottsdale, Ariz. headquarters, Dial reports. Henkel announced plans to acquire the personal care company for $2.9 bil. in cash in December; under the proposed agreement, Dial shareholders would receive $28.75 per share. The acquisition, expected to close in April, also is subject to regulatory approval (1"The Rose Sheet" Dec. 22, 2003, p. 3)...
You may also be interested in...
Dial shareholder settlement
Dial announces proposed settlement of all shareholder lawsuits filed against the firm relating to Henkel's proposed acquisition of the company. Under terms of the agreement, Dial and Henkel will reduce proposed termination fee payable by Dial to Henkel from $110 mil. to $85 mil., firm reports. The settlement is subject to court approval and consummation of the pending merger, Dial notes. The lawsuits, filed after Henkel and Dial announced the acquisition in December, allege Dial's board of directors "breached its fiduciary duties by agreeing to enter into the merger agreement with Henkel on the terms provided." Shareholders will vote on proposed acquisition March 24 in a special meeting at Dial's Scottsdale, Ariz. headquarters (1"The Rose Sheet" Feb. 23, 2004, In Brief)...
Henkel’s $2.9 Bil. Dial Acquisition To Bolster U.S. Presence
Henkel's acquisition of Dial will strengthen the German firm's North American business by bolstering its personal care portfolio with the addition of the Dial, Coast and Tone soap brands, the company said, announcing the planned acquisition Dec. 15
New EU Approvals
The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add two new products, including Ryzneuta, Evive Biotechnology's treatment for chemotherapy-induced neutropenia.